Recombinant Human Tumor Necrosis Factor-α Receptor II for Treatment of Rheumatoid Arthritis

Objective To evaluate the effect and safety of recomnbinant human tumor necrosis factor-α Receptor Ⅱ(etanercept)for treatment of rheumatoid arthritis(RA).Methods 89 patients were divided into control group and trial group randomly.25 mg etanercept was given to trial group twice a week by subcutaneous injection;While the control group accepted methotrexat(MTX)12.5 mg once a week orally,the course of treatment was 12 weeks.Results ACR20 effective rate of etanercept was 44.40% after treatment for 2 weeks,while the control group was 22.50%,group comparison has statistical significance(P0.05).After 8 weeks,there was statistical difference between two groups(P0.05).In the 12th weeks,the ACR20 effective rate of etanercept raised to 66.70% while the control group was 42.50%,group comparison has statistical significance(P0.05).Of safety,as well as side effect has no difference in two groups.Conclusion In comparison with MTX orally for treatment of activated rheumatoid arthritis,etanercept relieves symptoms more quickly,and it has satisfactory safety and significant effect.